166 related articles for article (PubMed ID: 25174501)
1. Editorial: The Innovative Medicines Initiative--collaborations are key to innovating R&D processes.
Laverty H; Goldman M
Biotechnol J; 2014 Sep; 9(9):1095-6. PubMed ID: 25174501
[No Abstract] [Full Text] [Related]
2. Trial watch: personalized medicines in late-stage development.
Milne CP; Garafalo S; Bryan C; McKiernan M
Nat Rev Drug Discov; 2014 May; 13(5):324-5. PubMed ID: 24781541
[No Abstract] [Full Text] [Related]
3. The innovative medicines initiative: a case study for new ways of working in drug R&D.
Laverty H; Goldman M
Future Med Chem; 2014 Apr; 6(5):489-91. PubMed ID: 24649951
[No Abstract] [Full Text] [Related]
4. News & Analysis: new initiative aims to improve success of early stage drug discovery.
Coaker H
Future Med Chem; 2014 May; 6(7):733. PubMed ID: 24941869
[No Abstract] [Full Text] [Related]
5. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
Godman B; Malmström RE; Diogene E; Gray A; Jayathissa S; Timoney A; Acurcio F; Alkan A; Brzezinska A; Bucsics A; Campbell SM; Czeczot J; de Bruyn W; Eriksson I; Yusof FA; Finlayson AE; Fürst J; Garuoliene K; Guerra Júnior A; Gulbinovič J; Jan S; Joppi R; Kalaba M; Magnisson E; McCullagh L; Miikkulainen K; Ofierska-Sujkowska G; Pedersen HB; Selke G; Sermet C; Spillane S; Supian A; Truter I; Vlahović-Palčevski V; Vien LE; Vural EH; Wale J; Władysiuk M; Zeng W; Gustafsson LL
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):77-94. PubMed ID: 25487078
[TBL] [Abstract][Full Text] [Related]
6. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
Woosley RL; Myers RT; Goodsaid F
Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
[TBL] [Abstract][Full Text] [Related]
7. Personalized medicine: a paradigm for a sustainable pharmaceutical industry?
Chackalamannil S; Desai MC
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):443-5. PubMed ID: 19562640
[TBL] [Abstract][Full Text] [Related]
8. Grants4Targets: an open innovation initiative to foster drug discovery collaborations.
Dorsch H; Jurock AE; Schoepe S; Lessl M; Asadullah K
Nat Rev Drug Discov; 2015 Jan; 14(1):74-6. PubMed ID: 25430867
[No Abstract] [Full Text] [Related]
9. Pharmacotherapy crisis in the spotlight--is open collaboration between academia and industry the answer?
Kaski JC
Cardiovasc Drugs Ther; 2011 Apr; 25(2):187-8. PubMed ID: 21503624
[No Abstract] [Full Text] [Related]
10. Organizing for innovation: towards successful translational research.
West W; Nightingale P
Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
[TBL] [Abstract][Full Text] [Related]
11. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
Betz UA
Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
[TBL] [Abstract][Full Text] [Related]
12. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
Perakslis ED; Van Dam J; Szalma S
Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
[No Abstract] [Full Text] [Related]
13. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
Vallance P; Williams P; Dollery C
Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
[No Abstract] [Full Text] [Related]
14. U-BIOPRED: evaluation of the value of a public-private partnership to industry.
Riley JH; Erpenbeck VJ; Matthews JG; Holweg CTJ; Compton C; Seibold W; Higenbottam T; Wagers S; Rowe A; Myles D;
Drug Discov Today; 2018 Sep; 23(9):1622-1634. PubMed ID: 29936248
[TBL] [Abstract][Full Text] [Related]
15. [PHARMACEUTICAL INDUSTRY AND PERSONALIZED MEDICINE: A PARADIGM SHIFT IN THE DEVELOPMENT OF NEW DRUGS].
Scheen AJ
Rev Med Liege; 2015; 70(5-6):237-41. PubMed ID: 26285445
[TBL] [Abstract][Full Text] [Related]
16. Overcoming the obstacles in the pharma/biotech industry: 2009 update.
Graul AI; Revel L; Tell M; Rosa E; Cruces E
Drug News Perspect; 2010; 23(1):48-63. PubMed ID: 20155219
[TBL] [Abstract][Full Text] [Related]
17. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
Litten RZ; Ryan M; Falk D; Fertig J
Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
[TBL] [Abstract][Full Text] [Related]
18. Digital health center at UCSF clears the path for innovation. The new initiative aims to drive precision medicine forward. Interview by Rajiv Leventhal.
Blum M
Healthc Inform; 2013 Sep; 30(6):44-6. PubMed ID: 24224343
[No Abstract] [Full Text] [Related]
19. The critical path initiative: leveraging collaborations to enhance regulatory science.
Barratt RA; Bowens SL; McCune SK; Johannessen JN; Buckman SY
Clin Pharmacol Ther; 2012 Mar; 91(3):380-3. PubMed ID: 22343813
[TBL] [Abstract][Full Text] [Related]
20. R&D returns continue to fall.
Mullard A
Nat Rev Drug Discov; 2016 Dec; 16(1):9. PubMed ID: 28031564
[No Abstract] [Full Text] [Related]
[Next] [New Search]
